{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:53:07Z","timestamp":1792173187564,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.82360052"],"award-info":[{"award-number":["No.82360052"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s13300-024-01594-7","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T08:02:09Z","timestamp":1716364929000},"page":"1717-1733","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide Tablets): A Real-World Study Based on FAERS from 2019 to 2023"],"prefix":"10.1007","volume":"15","author":[{"given":"Si","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyu","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuitao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9815-278X","authenticated-orcid":false,"given":"Changjun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"1594_CR1","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/nm.3616","volume":"20","author":"J Yan","year":"2014","unstructured":"Yan J, et al. Obesity- and aging-induced excess of central transforming growth factor-\u03b2 potentiates diabetic development via an RNA stress response. Nat Med. 2014;20:1001\u20138.","journal-title":"Nat Med"},{"key":"1594_CR2","unstructured":"A 16-year prospective cohort study to evaluate effects of long-term fluctuations in obesity indices of prediabetics on the incidence of future diabetes - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/34079024\/. Accessed 3 Mar 2024."},{"key":"1594_CR3","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","volume":"80","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The global burden of cardiovascular diseases and risk. J Am Coll Cardiol. 2022;80:2361\u201371.","journal-title":"J Am Coll Cardiol"},{"key":"1594_CR4","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1093\/eurheartj\/ehab758","volume":"43","author":"DA Hess","year":"2022","unstructured":"Hess DA, et al. Vascular repair and regeneration in cardiometabolic diseases. Eur Heart J. 2022;43:450\u20139.","journal-title":"Eur Heart J"},{"key":"1594_CR5","unstructured":"Cardiometabolic-based chronic disease, adiposity and dysglycemia drivers: JACC state-of-the-art review - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/32029136\/. Accessed 3 Mar 2024."},{"key":"1594_CR6","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 2022;45:2753\u201386.","journal-title":"Diabetes Care"},{"key":"1594_CR7","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nbt.3623","volume":"34","author":"M Sarangdhar","year":"2016","unstructured":"Sarangdhar M, et al. Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data. Nat Biotechnol. 2016;34:697\u2013700.","journal-title":"Nat Biotechnol"},{"key":"1594_CR8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug. 2004;13:519\u201323.","journal-title":"Pharmacoepidemiol Drug"},{"key":"1594_CR9","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2165\/00002018-200528100-00006","volume":"28","author":"E Heeley","year":"2005","unstructured":"Heeley E, Waller P, Moseley J. Testing and implementing signal impact analysis in a regulatory setting. Drug Saf. 2005;28:901\u20136.","journal-title":"Drug Saf"},{"key":"1594_CR10","unstructured":"A Bayesian neural network method for adverse drug reaction signal generation - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/9696956\/. Accessed 3 Mar 2024."},{"key":"1594_CR11","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1002\/sim.8745","volume":"39","author":"S Heo","year":"2020","unstructured":"Heo S, Jung I. Extended multi-item gamma Poisson shrinker methods based on the zero-inflated Poisson model for postmarket drug safety surveillance. Stat Med. 2020;39:4636\u201350.","journal-title":"Stat Med"},{"key":"1594_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","volume":"346","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, et al. Safety assessment of brexpiprazole: real-world adverse event analysis from the FAERS database. J Affect Disord. 2024;346:223\u20139.","journal-title":"J Affect Disord"},{"key":"1594_CR13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.7326\/M22-2904","volume":"176","author":"SD Navaneethan","year":"2023","unstructured":"Navaneethan SD, et al. Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update. Ann Intern Med. 2023;176:381\u20137.","journal-title":"Ann Intern Med"},{"key":"1594_CR14","unstructured":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/36148880\/. Accessed 3 Mar 2024."},{"key":"1594_CR15","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc24-S009","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment\u202f: standards of care in diabetes\u20142024. Diabetes Care. 2024;47:S158\u201378.","journal-title":"Diabetes Care"},{"key":"1594_CR16","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2017.14752","volume":"318","author":"M Davies","year":"2017","unstructured":"Davies M, et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes. JAMA. 2017;318:1460.","journal-title":"JAMA"},{"key":"1594_CR17","unstructured":"Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): An open-label, randomised, active-controlled, phase 3a trial - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/32333876\/."},{"key":"1594_CR18","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.2337\/dc19-0749","volume":"42","author":"VR Aroda","year":"2019","unstructured":"Aroda VR, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42:1724\u201332.","journal-title":"Diabetes Care"},{"key":"1594_CR19","unstructured":"Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): A multicentre, randomised, phase 3b trial - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/37385279\/. Accessed 3 Mar 2024."},{"key":"1594_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","volume":"394","author":"R Pratley","year":"2019","unstructured":"Pratley R, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. The Lancet. 2019;394:39\u201350.","journal-title":"The Lancet"},{"key":"1594_CR21","unstructured":"Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/30429357\/. Accessed 3 Mar 2024."},{"key":"1594_CR22","unstructured":"A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/35838946\/. Accessed 3 Mar 2024."},{"key":"1594_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.996179","volume":"10","author":"Y Shu","year":"2022","unstructured":"Shu Y, et al. Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system. Front Public Health. 2022;10: 996179.","journal-title":"Front Public Health"},{"key":"1594_CR24","unstructured":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/29049653\/."},{"key":"1594_CR25","unstructured":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): A double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/28110911\/. Accessed 3 Mar 2024."},{"key":"1594_CR26","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834\u201344.","journal-title":"N Engl J Med"},{"key":"1594_CR27","unstructured":"PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/31186300\/. Accessed 3 Mar 2024."},{"key":"1594_CR28","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/dom.12885","volume":"19","author":"H Storgaard","year":"2017","unstructured":"Storgaard H, Cold F, Gluud LL, Vilsb\u00f8ll T, Knop FK. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19:906\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"1594_CR29","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3389\/fphar.2018.00576","volume":"9","author":"F-H Shi","year":"2018","unstructured":"Shi F-H, et al. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2018;9:576.","journal-title":"Front Pharmacol"},{"key":"1594_CR30","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9:653\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1594_CR31","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7:515\u201327.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1594_CR32","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381:841\u201351.","journal-title":"N Engl J Med"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-024-01594-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-024-01594-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-024-01594-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T18:14:05Z","timestamp":1721672045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-024-01594-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1594"],"URL":"https:\/\/doi.org\/10.1007\/s13300-024-01594-7","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,22]]},"assertion":[{"value":"10 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no competing interests. Si Xiong, Ruoyu Gou, Xudong Liang, Hao Wu, Shuitao Qin, Bing Li, Changjun Luo, and Junan Chen declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The research\u2019s underpinning data was sourced from the FAERS database (FDA Adverse Event Reporting System) which is a publicly available database with de-identified data ()<b>.<\/b>","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}